290 related articles for article (PubMed ID: 19446617)
1. Quality by design approach to understand the process of nanosuspension preparation.
Verma S; Lan Y; Gokhale R; Burgess DJ
Int J Pharm; 2009 Jul; 377(1-2):185-98. PubMed ID: 19446617
[TBL] [Abstract][Full Text] [Related]
2. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions.
Verma S; Gokhale R; Burgess DJ
Int J Pharm; 2009 Oct; 380(1-2):216-22. PubMed ID: 19596059
[TBL] [Abstract][Full Text] [Related]
4. Quality by Design approach to spray drying processing of crystalline nanosuspensions.
Kumar S; Gokhale R; Burgess DJ
Int J Pharm; 2014 Apr; 464(1-2):234-42. PubMed ID: 24412337
[TBL] [Abstract][Full Text] [Related]
5. Quality by design - Spray drying of insulin intended for inhalation.
Maltesen MJ; Bjerregaard S; Hovgaard L; Havelund S; van de Weert M
Eur J Pharm Biopharm; 2008 Nov; 70(3):828-38. PubMed ID: 18755270
[TBL] [Abstract][Full Text] [Related]
6. Identification of critical process parameters and its interplay with nanosuspension formulation prepared by top down media milling technology--a QbD perspective.
Ghosh I; Schenck D; Bose S; Liu F; Motto M
Pharm Dev Technol; 2013; 18(3):719-29. PubMed ID: 23061898
[TBL] [Abstract][Full Text] [Related]
7. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology.
Teeranachaideekul V; Junyaprasert VB; Souto EB; Müller RH
Int J Pharm; 2008 Apr; 354(1-2):227-34. PubMed ID: 18242898
[TBL] [Abstract][Full Text] [Related]
8. Preparation of a chemically stable quercetin formulation using nanosuspension technology.
Gao L; Liu G; Wang X; Liu F; Xu Y; Ma J
Int J Pharm; 2011 Feb; 404(1-2):231-7. PubMed ID: 21093559
[TBL] [Abstract][Full Text] [Related]
9. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
[TBL] [Abstract][Full Text] [Related]
10. Application of Box-Behnken design in understanding the quality of genistein self-nanoemulsified drug delivery systems and optimizing its formulation.
Zhu S; Hong M; Liu C; Pei Y
Pharm Dev Technol; 2009; 14(6):642-9. PubMed ID: 19883253
[TBL] [Abstract][Full Text] [Related]
11. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide.
Singh SK; Srinivasan KK; Gowthamarajan K; Singare DS; Prakash D; Gaikwad NB
Eur J Pharm Biopharm; 2011 Aug; 78(3):441-6. PubMed ID: 21439378
[TBL] [Abstract][Full Text] [Related]
12. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications.
Deng Z; Xu S; Li S
Int J Pharm; 2008 Mar; 351(1-2):236-43. PubMed ID: 18093763
[TBL] [Abstract][Full Text] [Related]
13. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors.
Ali HS; York P; Blagden N
Int J Pharm; 2009 Jun; 375(1-2):107-13. PubMed ID: 19481696
[TBL] [Abstract][Full Text] [Related]
14. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability.
Xia D; Quan P; Piao H; Piao H; Sun S; Yin Y; Cui F
Eur J Pharm Sci; 2010 Jul; 40(4):325-34. PubMed ID: 20417274
[TBL] [Abstract][Full Text] [Related]
15. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
Pardeike J; Strohmeier DM; Schrödl N; Voura C; Gruber M; Khinast JG; Zimmer A
Int J Pharm; 2011 Nov; 420(1):93-100. PubMed ID: 21889582
[TBL] [Abstract][Full Text] [Related]
16. A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale.
Xu X; Khan MA; Burgess DJ
Int J Pharm; 2012 Feb; 423(2):543-53. PubMed ID: 22155413
[TBL] [Abstract][Full Text] [Related]
17. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18.
Pardeike J; Müller RH
Int J Pharm; 2010 May; 391(1-2):322-9. PubMed ID: 20214969
[TBL] [Abstract][Full Text] [Related]
18. Spray-drying process optimization for manufacture of drug-cyclodextrin complex powder using design of experiments.
Nekkanti V; Muniyappan T; Karatgi P; Hari MS; Marella S; Pillai R
Drug Dev Ind Pharm; 2009 Oct; 35(10):1219-29. PubMed ID: 19555246
[TBL] [Abstract][Full Text] [Related]
19. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of paclitaxel nanoparticles using a quality-by-design approach.
Yerlikaya F; Ozgen A; Vural I; Guven O; Karaagaoglu E; Khan MA; Capan Y
J Pharm Sci; 2013 Oct; 102(10):3748-61. PubMed ID: 23918313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
